Consequently, CCT2 inhibition through dihydroartemisinin, a derivative of artemisinin, resulted in the inhibition of the KRAS signaling pathway and suppressed GBM malignant progression, providing a new idea for GBM treatment [68]. The gene discussed is CCT2; the disease is glioblastoma.